COLO699 Xenograft Model Overview
The COLO699 xenograft model is derived from a human large cell carcinoma of the lung and serves as a valuable in vivo system for studying aggressive non-small cell lung cancer (NSCLC) subtypes that lack canonical driver mutations. Originating from a male patient, the COLO699 cell line exhibits poorly differentiated morphology and supports tumor formation in immunodeficient mice, making it appropriate for preclinical evaluation of broad-spectrum therapeutics and mechanistic studies involving poorly characterized oncogenic processes. The model is frequently utilized in research focused on cell cycle regulation, apoptosis resistance, and drug delivery strategies in the context of large cell carcinoma, a histological subtype often associated with poor prognosis and limited therapeutic responsiveness.
Request a Custom Quote for COLO699 Xenograft ModelBiological and Molecular Characteristics
The COLO699 cell line lacks activating mutations in common NSCLC-associated oncogenes such as EGFR, KRAS, and ALK, making it a representative model for studying non-oncogene–addicted lung tumors. It exhibits high levels of cell proliferation and displays partial epithelial characteristics with expression of cytokeratin 7 and focal E-cadherin staining. The tumor suppressor TP53 is frequently inactivated, contributing to genomic instability and deregulated apoptosis. In addition, the cells show minimal PD-L1 expression and downregulation of antigen presentation machinery, features consistent with an immune-evasive phenotype. These characteristics make the COLO699 model suitable for testing cytotoxic agents, mitotic checkpoint inhibitors, and immune-sensitization strategies in hard-to-treat NSCLC cases.
| Characteristic | Description |
|---|---|
| Tissue Origin | Human lung (large cell carcinoma) |
| Mutation Profile | EGFR, KRAS, ALK wild-type; TP53 inactivated |
| Cell Morphology | Poorly differentiated, adherent |
| Immunomarkers | CK7+, partial E-cadherin+, PD-L1 (low) |
| Therapeutic Relevance | Non-oncogene–addicted NSCLC, drug resistance models |
In Vivo Model Development and Tumorigenicity
The COLO699 xenograft model is typically established via subcutaneous injection into immunodeficient mice, including athymic nude and NOD/SCID strains. Tumor take is generally robust, with palpable nodules forming within two weeks and progressing to measurable volumes within five to six weeks. Tumor growth is moderate to rapid, enabling experimental design with defined treatment windows. Due to its undifferentiated morphology and lack of dominant oncogenic drivers, the model is ideal for evaluating cytotoxic chemotherapy agents, multi-kinase inhibitors, and investigational compounds targeting noncanonical growth and survival pathways. Its reliable engraftment and consistent growth kinetics allow for reproducible testing across treatment arms and combination regimens.
Request a Custom Quote for COLO699 Xenograft ModelHistopathology and Immunohistochemical Profile
Histologic analysis of COLO699-derived tumors reveals large, pleomorphic tumor cells with prominent nucleoli, scant cytoplasm, and high mitotic activity. Tumors display solid growth patterns with minimal glandular differentiation, consistent with poorly differentiated large cell carcinoma. Hematoxylin and eosin staining highlights hyperchromatic nuclei and occasional areas of necrosis. Immunohistochemistry demonstrates patchy cytokeratin 7 positivity and weak E-cadherin expression, confirming partial epithelial lineage. Ki-67 labeling index typically exceeds 60%, consistent with the model’s proliferative nature. TP53 loss is evidenced by nuclear accumulation of mutant protein, and PD-L1 expression is limited, supporting the model’s utility in immunotherapy resistance studies.
Preclinical Applications and Drug Response
The COLO699 xenograft model has been employed in a variety of preclinical investigations targeting poorly differentiated, treatment-resistant NSCLC. Due to its absence of targetable mutations, it provides a relevant system for assessing the efficacy of broad-acting agents such as platinum-based chemotherapies, taxanes, and anti-mitotic compounds. It is also used to explore mechanisms of acquired resistance, cell cycle deregulation, and apoptotic evasion. The model has shown variable responsiveness to experimental kinase inhibitors and is particularly valuable in testing nanoparticle-encapsulated therapies and antibody–drug conjugates aimed at enhancing intratumoral drug delivery. Its low PD-L1 expression makes it a candidate for evaluating immunostimulatory agents and adjuvant strategies designed to convert immune-cold tumors into responsive phenotypes.
Request This Model
To request the COLO699 xenograft model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for COLO699 Xenograft Model